SGX942 FDA Approval Status

FDA Approved: No
Brand name: SGX942
Generic name: dusquetide
Company: Soligenix, Inc.
Treatment for: Mucositis

SGX942 (dusquetide) is an innate defense regulator (IDR) in development for the treatment of oral mucositis.

Development timeline for SGX942

Date	Article
Jul 27, 2017	Soligenix Initiates Pivotal Phase 3 Clinical Trial of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Aug 18, 2016	FDA Grants Soligenix Orphan Drug Designation for Dusquetide for Treatment of Macrophage Activation Syndrome
Jun 3, 2013	FDA Grants Soligenix "Fast Track" Designation for SGX942 for the Treatment of Oral Mucositis in Patients with Head and Neck Cancer

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.